Fluoroscopy | Jotup

SwiftDuct Presents Positive Clinical Study Results of SwiftGlide For ERCP Procedures at ESGE Days 2024

Retrieved on:

Donnerstag, Mai 2, 2024

Electrochemistry, Dielectric spectroscopy, Bar-Ilan University, Poster, Gastrointestinal Endoscopy, Trial of the century, ESGE, Fluoroscopy, Bile, Pancreatic duct, Patient, EMMS Nazareth Hospital, Pancreatitis, Galilee Medical Center, Assistant, ERCP, Clinical trial, Medical imaging

SAKHNIN, Israel, May 2, 2024 /PRNewswire/ -- In a poster presentation at the 2024 annual meeting of the European Society of Gastrointestinal Endoscopy, ESGE Days 2024, SwiftDuct announced the positive findings of the first clinical trial of SwiftGlide™, the company's electrochemical navigation system for ERCP procedures.

Key Points:

SwiftDuct's first clinical study, which was conducted at Galilee Medical Center, demonstrates that the company's electrochemical navigation method has the potential to improve ERCP procedures and outcomes, marking an important milestone towards Fluoroscopy-Free ERCP cannulation.
ERCP is a widely used procedure to diagnose and treat issues in the bile or pancreatic ducts.
SAKHNIN, Israel, May 2, 2024 /PRNewswire/ -- In a poster presentation at the 2024 annual meeting of the European Society of Gastrointestinal Endoscopy, ESGE Days 2024 , SwiftDuct announced the positive findings of the first clinical trial of SwiftGlide™, the company's electrochemical navigation system for ERCP procedures.
The study showed that SwiftGlide™ was successful in differentiating between bile and pancreatic/mixed juices as the basis to providing selective and safe biliary cannulation during ERCP procedures.

New Field Data Shows High Diagnostic Yield for Lung Biopsy Diagnosis Using the Galaxy System™

Retrieved on:

Donnerstag, April 18, 2024

University, Cancer, Pleural cavity, Lung cancer, Galaxy, Fluoroscopy, Physician, Inova Fairfax Hospital, Lung, Diagnosis, SAN, Medical device

Key findings include:

Key Points:

Key findings include:
The papers reported diagnostic yield with a range of 92-96% observed by Dr. Hogarth and 96% by Dr. Mahajan.
The average lesion size ranged from 14mm to 16mm, with more than one-third of them less than or equal to 10mm in size.
The University of Chicago’s Dr. Kyle Hogarth was the first user of the Galaxy System in the United States.
The whitepapers, based on data obtained from Dr. Hogarth and Dr. Mahajan, are now available and can be found here .

Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

Retrieved on:

Dienstag, März 19, 2024

Food and Drug Administration, Blood, CE, Fluoroscopy, Atherosclerosis, Death, Plaque, United, Artery, MMSI, FDA, Health, Food, Electric motor

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System.

Key Points:

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System.
Merit also intends to file Micro ACE for CE mark designation.
The Micro ACE system is the latest innovation in the Merit Vascular portfolio.
Combining a balance of stiffness and resiliency, Micro ACE is designed to achieve micro-access in a wide range of vascular anatomies.

Vektor Medical Announces Publication of vMap Study Results in Journal of Cardiovascular Electrophysiology

Retrieved on:

Dienstag, April 2, 2024

Health, FDA, Technology, Photography, Health Technology, Artificial Intelligence, Cardiology, Arrhythmia, Artificial intelligence, Patient, Fluoroscopy, Journal, Medicine, AI, Medical imaging

Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy.

Key Points:

Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy.
The study , “Impact Of Artificial Intelligence Arrhythmia Mapping on Time to First Ablation, Procedure Duration, and Fluoroscopy Use,” is a retrospective, case-controlled study of 28 patients with common arrhythmia types.
“By employing AI ECG arrhythmia mapping using 12-lead ECG data, the study shows increased procedural efficiency and improved patient safety by limiting exposure to fluoroscopy.
EPs can rely on vMap to reduce procedure times with increased confidence in positive outcomes.

Noah Medical Named a “Fierce 15” Company of 2023 by Fierce MedTech

Retrieved on:

Mittwoch, März 6, 2024

SAN, Fierce, Physician, Growth, Silicon, Fluoroscopy, Medtech, Patient, Lung cancer, Galaxy, Diagnosis, Noah, Medical device

SAN CARLOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical announced today that Fierce MedTech has named it one of 2023’s “Fierce 15” medical technology companies.

Key Points:

SAN CARLOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical announced today that Fierce MedTech has named it one of 2023’s “Fierce 15” medical technology companies.
“Winning the Fierce 15 award is a shared triumph for both our exceptional team at Noah and the customers who’ve played an instrumental role in making Galaxy a leader in minimally invasive early lung cancer diagnosis,” said Noah Medical CEO Jian Zhang.
The Galaxy System was also recently recognized as a Medtech Breakthrough winner and named a finalist in the 2023 Fierce Innovation Awards: Life Sciences Edition.
“These companies exemplify the ability of the MedTech industry to turn cutting-edge ideas into meaningful outcomes and make them accessible on a large scale.”
To learn more about Noah Medical and the Galaxy System, please visit noahmed.com .

AOFAS Honors Two Female Orthopaedic Leaders

Retrieved on:

Dienstag, Februar 27, 2024

“I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”

Key Points:

“I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”
Over the past 15 years, Dr. Chou has conducted several research studies to examine breast cancer prevalence among female orthopaedic surgeons.
Dr. Chou’s research results confirmed higher breast cancer prevalence among female orthopaedic surgeons than the general population, and in a later study, she discovered higher prevalence among female orthopaedic surgeons compared to women in other surgical specialties.
Currently, she is leading a study to evaluate cancer risk associated with radiation exposure in male and female orthopaedic surgeons.
I applaud AOFAS for taking that initiative with these awards.”
Funding for the AOFAS Women’s Leadership Initiative is provided by the Orthopaedic Foot & Ankle Foundation, supported by a grant from Treace Medical Concepts, Inc.

Body Vision Medical Announces Successful Validation of LungVision™ System with Fujifilm's Range of Surgical C-arms

Retrieved on:

Dienstag, März 5, 2024

Marketing, Red Dot, Artificial intelligence, Physician, Biopsy, Thought, Fluoroscopy, Global health, Fujifilm, Medical imaging, Patient, Survival, Lung cancer, Diagnosis

CAMPBELL, Calif., March 5, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today the successful validation of Body Vision's LungVision™ system with FUJIFILM Healthcare Americas Corporation's Persona line of C-arms and FDR Cross two-in-one fluoroscopy C-arm and portable digital radiography solution.

Key Points:

CAMPBELL, Calif., March 5, 2024 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today the successful validation of Body Vision's LungVision™ system with FUJIFILM Healthcare Americas Corporation's Persona line of C-arms and FDR Cross two-in-one fluoroscopy C-arm and portable digital radiography solution.
Body Vision Medical's LungVision™ system uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans.
"This validation further demonstrates the power of an AI-driven imaging platform like LungVision™ that enables physicians to agnostically leverage our image-guided navigation and real-time imaging with the bronchoscopy platform and C-arm of their choice," said David Webster, CEO of Body Vision Medical.
"We're elated to see the successful validation of our C-arm platforms with Body Vision's leading LungVision™ system to synergistically provide the visualization needed by bronchoscopists during navigation bronchoscopy".

EmergeOrtho--Triangle Region Welcomes Dr. Ryan McCarter

Retrieved on:

Montag, März 4, 2024

Neck pain, Spine, Quality of life, Raleigh, North Carolina, Fluoroscopy, Rehabilitation, Patient, Spinal stenosis, Physiology, Low back pain, Sports medicine, MRI, Nursing

DURHAM, N.C., March 4, 2024 /PRNewswire/ -- EmergeOrtho—Triangle Region welcomes Dr. Ryan McCarter, a highly esteemed Physical Medicine and Rehabilitation specialist, focusing on Interventional Spine and Musculoskeletal Medicine.

Key Points:

DURHAM, N.C., March 4, 2024 /PRNewswire/ -- EmergeOrtho—Triangle Region welcomes Dr. Ryan McCarter, a highly esteemed Physical Medicine and Rehabilitation specialist, focusing on Interventional Spine and Musculoskeletal Medicine.
"I'm excited to join the EmergeOrtho team and contribute to the mission of delivering top-tier orthopedic and musculoskeletal care," said Dr. McCarter.
"As a physician, my goal is to empower each patient on their journey to recovery," said Dr. McCarter.
To seek pain treatment, schedule an appointment with Dr. Ryan McCarter.

Global Veterinary Computed Tomography Scanner Market Analysis & Forecast 2024-2034, Featuring Epica Animal Health, Asto CT, Hallmarq Veterinary Imaging, Xoran Technologies & Isabelle Vets

Retrieved on:

Montag, Februar 12, 2024

Pet, Livestock, USD, Zoonosis, Animal, Injury, Dog, Traumatology, Prevalence, Health, Pithing, Cat, CBCT, Fluoroscopy, Research, Cancer, Medical imaging

DUBLIN, Feb. 12, 2024 /PRNewswire/ -- The "Global Veterinary Computed Tomography Scanner Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Feb. 12, 2024 /PRNewswire/ -- The "Global Veterinary Computed Tomography Scanner Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.
Rise in technologically advanced product launches for treating animal diseases is predicted to boost the market growth during the forecast period.
The veterinary computed tomography scanner is expected to see increased demand, driven by a preference among pet practitioners for its superior diagnostic capabilities.
By end-user, veterinary hospitals was the highest revenue-grossing segment in the global veterinary computed tomography scanner market in 2023 owing to growing focus on development of new technologies, increasing technological advancements, and rising initiatives by market players.

Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium

Retrieved on:

Samstag, Februar 3, 2024

IRVINE, Calif., Feb. 2, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced 12-month results from the company-sponsored inspIRE study, "Predictors of Success for Pulmonary Vein Isolation with Pulsed Field Ablation (PFA) Using a Variable Loop Catheter with 3D Mapping Integration: Complete 12-month outcomes from inspIRE," presented as a late-breaking presentation at the 29th Annual International AF Symposium.1 Interim results from the company-sponsored admIRE study, titled "PFA Using a Variable Loop Circular Catheter with 3D Mapping Integration: Early Outcomes of the admIRE Study," were also shared in a late-breaking presentation.2

Key Points:

The CARTO™ System enables an intuitive and reproducible workflow with real-time visualization and feedback mechanisms.
"Biosense Webster is committed to bringing forward a versatile, differentiated portfolio of PFA solutions designed to help electrophysiologists deliver safe, effective, and efficient cardiac ablation procedures," said Jasmina Brooks, President, Biosense Webster, Inc. "The encouraging outcomes from clinical trials with VARIPULSE™ fuel our excitement as we continue to deliver innovations to meet the diverse needs and ablation strategies required to successfully treat atrial fibrillation."
The inspIRE study evaluated the safety and effectiveness of the VARIPULSE™ Platform for the treatment of drug-refractory paroxysmal AFib in Europe and Canada.1 In the study, the primary effectiveness endpoint of acute pulmonary vein isolation and 12-month freedom from atrial arrhythmia recurrence (AFib, Atrial Tachycardia, or Atrial Flutter) was 75.6%.
Among participants receiving optimal PFA applications, 80% achieved the primary effectiveness endpoint.1 The study reported a low fluoroscopy time of 7.8 minutes, partly attributed to the integration of the VARIPULSE™ Platform to the CARTO™ 3 System.